SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Marie Claire Van Hout, An Internet Study of User’s Experiences of the Synthetic Cathinone 4-Methylethcathinone (4-MEC), Journal of Psychoactive Drugs, 2014, 46, 4, 273

    CrossRef

  2. 2
    John R. Richards, Robert W. Derlet, Beta-Blocker and Antipsychotic Treatment of Toxicity from So-called Designer Drugs, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014, 34, 8
  3. 3
    Mariana Angoa-Pérez, Michael J. Kane, Nieves Herrera-Mundo, Dina M. Francescutti, Donald M. Kuhn, Effects of combined treatment with mephedrone and methamphetamine or 3,4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus, Life Sciences, 2014, 97, 1, 31

    CrossRef

  4. 4
    Michael E. Nelson, Sean M. Bryant, Steven E. Aks, Emerging drugs of abuse, Disease-a-Month, 2014, 60, 3, 110

    CrossRef

  5. 5
    Michael E. Nelson, Sean M. Bryant, Steven E. Aks, Emerging Drugs of Abuse, Emergency Medicine Clinics of North America, 2014, 32, 1, 1

    CrossRef

  6. 6
    Maria João Valente, Paula Guedes de Pinho, Maria de Lourdes Bastos, Félix Carvalho, Márcia Carvalho, Khat and synthetic cathinones: a review, Archives of Toxicology, 2014, 88, 1, 15

    CrossRef

  7. 7
    Bryan Lee Miller, John M. Stogner, Not-So-Clean Fun: A Profile of Bath Salt Users Among a College Sample in the United States, Journal of Psychoactive Drugs, 2014, 46, 2, 147

    CrossRef

  8. 8
    Julie A. Marusich, Kateland R. Antonazzo, Jenny L. Wiley, Bruce E. Blough, John S. Partilla, Michael H. Baumann, Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV), Neuropharmacology, 2014,

    CrossRef

  9. 9
    Silja Skogstad Tuv, Hege Krabseth, Ritva Karinen, Kirsten M. Olsen, Elisabeth L. Øiestad, Vigdis Vindenes, Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period, Accident Analysis & Prevention, 2014, 62, 26

    CrossRef

  10. 10
    Kristyn Tekulve, Andreia Alexander, Laura Tormoehlen, Seizures Associated With Synthetic Cathinone Exposures in the Pediatric Population, Pediatric Neurology, 2014, 51, 1, 67

    CrossRef

  11. 11
    Hanna Uosukainen, Ulrich Tacke, Adam R. Winstock, Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users, International Journal of Drug Policy, 2014,

    CrossRef

  12. 12
    Marisol S. Castaneto, David A. Gorelick, Nathalie A. Desrosiers, Rebecca L. Hartman, Sandrine Pirard, Marilyn A. Huestis, Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications, Drug and Alcohol Dependence, 2014,

    CrossRef

  13. 13
    Chris Wilkins, Paul Sweetsur, Karl Parker, The impact of the prohibition of benzylpiperazine (BZP) “legal highs” on the availability, price and strength of BZP in New Zealand, Drug and Alcohol Dependence, 2014,

    CrossRef

  14. 14
    A. R. Winstock, R. Borschmann, J. Bell, The non-medical use of tramadol in the UK: findings from a large community sample, International Journal of Clinical Practice, 2014, 68, 9
  15. You have free access to this content15
    A R Green, M V King, S E Shortall, K C F Fone, The preclinical pharmacology of mephedrone; not just MDMA by another name, British Journal of Pharmacology, 2014, 171, 9
  16. 16
    József Rácz, Róbert Csák, Sándor Lisznyai, Transition from “old” injected drugs to mephedrone in an urban micro segregate in Budapest, Hungary: a qualitative analysis, Journal of Substance Use, 2014, 1

    CrossRef

  17. 17
    Monica J. Barratt, Jason A. Ferris, Adam R. Winstock, Use of Silk Road, the online drug marketplace, in the United Kingdom, Australia and the United States, Addiction, 2014, 109, 5
  18. 18
    Karla D. Wagner, Richard F. Armenta, Alexis M. Roth, Jane C. Maxwell, Jazmine Cuevas-Mota, Richard S. Garfein, Use of synthetic cathinones and cannabimimetics among injection drug users in San Diego, California, Drug and Alcohol Dependence, 2014, 141, 99

    CrossRef

  19. 19
    Kayla N. Ellefsen, Sébastien Anizan, Marisol S. Castaneto, Nathalie A. Desrosiers, Thomas M. Martin, Kevin L. Klette, Marilyn A. Huestis, Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology, Drug Testing and Analysis, 2014, 6, 7-8
  20. 20
    Ornella Corazza, Zsolt Demetrovics, Wim van den Brink, Fabrizio Schifano, ‘Legal highs’ an inappropriate term for ‘Novel Psychoactive Drugs’ in drug prevention and scientific debate, International Journal of Drug Policy, 2013, 24, 1, 82

    CrossRef

  21. 21
    M. Coppola, R. Mondola, 5-Iodo-2-aminoindan (5-IAI): Chemistry, pharmacology, and toxicology of a research chemical producing MDMA-like effects, Toxicology Letters, 2013, 218, 1, 24

    CrossRef

  22. 22
    Sinead E. Shortall, Alice E. Macerola, Rabbi T.R. Swaby, Rebecca Jayson, Chantal Korsah, Katharine E. Pillidge, Peter M. Wigmore, Francis J.P. Ebling, A. Richard Green, Kevin C.F. Fone, Madeleine V. King, Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat, European Neuropsychopharmacology, 2013, 23, 9, 1085

    CrossRef

  23. 23
    M.L. Miller, K.M. Creehan, D. Angrish, D.J. Barlow, K.L. Houseknecht, T.J. Dickerson, M.A. Taffe, Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone), Drug and Alcohol Dependence, 2013, 127, 1-3, 248

    CrossRef

  24. 24
    Débora González, Mireia Ventura, Fernando Caudevilla, Marta Torrens, Magi Farre, Consumption of new psychoactive substances in a Spanish sample of research chemical users, Human Psychopharmacology: Clinical and Experimental, 2013, 28, 4
  25. 25
    Lucas A. Johnson, Rebecca L. Johnson, Ray-Bernard Portier, Current “Legal Highs”, The Journal of Emergency Medicine, 2013, 44, 6, 1108

    CrossRef

  26. 26
    Jolanta B. Zawilska, Jakub Wojcieszak, Designer cathinones—An emerging class of novel recreational drugs, Forensic Science International, 2013, 231, 1-3, 42

    CrossRef

  27. 27
    SE Shortall, AR Green, KM Swift, KCF Fone, MV King, Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterization of mephedrone-induced hypothermia, British Journal of Pharmacology, 2013, 168, 4
  28. 28
    Kelly E. Wood, Exposure to Bath Salts and Synthetic Tetrahydrocannabinol from 2009 to 2012 in the United States, The Journal of Pediatrics, 2013, 163, 1, 213

    CrossRef

  29. 29
    Paul Griffiths, Michael Evans-Brown, Roumen Sedefov, Getting up to speed with the public health and regulatory challenges posed by new psychoactive substances in the information age, Addiction, 2013, 108, 10
  30. 30
    J. R. H. Archer, P. I. Dargan, D. M. Wood, A. R. Winstock, Hospital and prehospital emergency service utilisation as an impact of acute recreational drug and ethanol toxicity, Journal of Substance Use, 2013, 18, 2, 129

    CrossRef

  31. 31
    Anders Just Pedersen, Lotte Ask Reitzel, Sys Stybe Johansen, Kristian Linnet, In vitro metabolism studies on mephedrone and analysis of forensic cases, Drug Testing and Analysis, 2013, 5, 6
  32. 32
    Daniela A. Herzig, Rowan Brooks, Christine Mohr, Inferring about individual drug and schizotypy effects on cognitive functioning in polydrug using mephedrone users before and after clubbing, Human Psychopharmacology: Clinical and Experimental, 2013, 28, 2
  33. 33
    Erik W. Gunderson, Matthew G. Kirkpatrick, Laura M. Willing, Christopher P. Holstege, Intranasal Substituted Cathinone “Bath Salts” Psychosis Potentially Exacerbated by Diphenhydramine, Journal of Addiction Medicine, 2013, 7, 3, 163

    CrossRef

  34. 34
    John M. Stogner, Bryan Lee Miller, Investigating the ‘bath salt’ panic: The rarity of synthetic cathinone use among students in the United States, Drug and Alcohol Review, 2013, 32, 5
  35. 35
    Aymeric Petit, Laurent Karila, Michel Sananes, Michel Lejoyeux, La méphédrone : une nouvelle drogue de synthèse, La Presse Médicale, 2013, 42, 10, 1310

    CrossRef

  36. 36
    Bjørnar den Hollander, Stanislav Rozov, Anni-Maija Linden, Mikko Uusi-Oukari, Ilkka Ojanperä, Esa R. Korpi, Long-term cognitive and neurochemical effects of “bath salt” designer drugs methylone and mephedrone, Pharmacology Biochemistry and Behavior, 2013, 103, 3, 501

    CrossRef

  37. 37
    Shawn M. Aarde, Deepshikha Angrish, Deborah J. Barlow, M. Jerry Wright Jr, Sophia A. Vandewater, Kevin M. Creehan, Karen L. Houseknecht, Tobin J. Dickerson, Michael A. Taffe, Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats, Addiction Biology, 2013, 18, 5
  38. 38
    Mariana Angoa-Pérez, Michael J. Kane, Denise I. Briggs, Dina M. Francescutti, Catherine E. Sykes, Mrudang M. Shah, David M. Thomas, Donald M. Kuhn, Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA, Journal of Neurochemistry, 2013, 125, 1
  39. 39
    Nicholas F. Dybdal-Hargreaves, Nicholas D. Holder, Paige E. Ottoson, Melanie D. Sweeney, Tyisha Williams, Mephedrone: Public health risk, mechanisms of action, and behavioral effects, European Journal of Pharmacology, 2013, 714, 1-3, 32

    CrossRef

  40. 40
    Brian C. Kelly, Brooke E. Wells, Mark Pawson, Amy Leclair, Jeffrey T. Parsons, Sarit A. Golub, Novel psychoactive drug use among younger adults involved in US nightlife scenes, Drug and Alcohol Review, 2013, 32, 6
  41. 41
    Pierluigi Simonato, Ornella Corazza, Paolo Santonastaso, John Corkery, Paolo Deluca, Zoe Davey, Ursula Blaszko, Fabrizio Schifano, Novel psychoactive substances as a novel challenge for health professionals: results from an Italian survey, Human Psychopharmacology: Clinical and Experimental, 2013, 28, 4
  42. 42
    LD Simmler, TA Buser, M Donzelli, Y Schramm, L-H Dieu, J Huwyler, S Chaboz, MC Hoener, ME Liechti, Pharmacological characterization of designer cathinones in vitro, British Journal of Pharmacology, 2013, 168, 2
  43. 43
    Dariusz Zuba, Bogumiła Byrska, Prevalence and co-existence of active components of ‘legal highs’, Drug Testing and Analysis, 2013, 5, 6
  44. 44
    Marta Concheiro, Sebastien Anizan, Kayla Ellefsen, Marilyn A. Huestis, Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry, Analytical and Bioanalytical Chemistry, 2013, 405, 29, 9437

    CrossRef

  45. 45
    Erik W. Gunderson, Matthew G. Kirkpatrick, Laura M. Willing, Christopher P. Holstege, Substituted Cathinone Products, Journal of Addiction Medicine, 2013, 7, 3, 153

    CrossRef

  46. 46
    Máté Kapitány-Fövény, Máté Kertész, Adam Winstock, Paolo Deluca, Ornella Corazza, Judit Farkas, Gábor Zacher, Róbert Urbán, Zsolt Demetrovics, Substitutional potential of mephedrone: an analysis of the subjective effects, Human Psychopharmacology: Clinical and Experimental, 2013, 28, 4
  47. 47
    Adam R. Winstock, Monica J. Barratt, Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample, Drug and Alcohol Dependence, 2013, 131, 1-2, 106

    CrossRef

  48. 48
    Adam R. Winstock, Monica J. Barratt, The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products, Human Psychopharmacology: Clinical and Experimental, 2013, 28, 4
  49. 49
    N. Shima, M. Katagi, H. Kamata, S. Matsuta, K. Nakanishi, K. Zaitsu, T. Kamata, H. Nishioka, A. Miki, M. Tatsuno, T. Sato, H. Tsuchihashi, K. Suzuki, Urinary excretion and metabolism of the newly encountered designer drug 3,4-dimethylmethcathinone in humans, Forensic Toxicology, 2013, 31, 1, 101

    CrossRef

  50. 50
    Foon Yin Lai, Phong K. Thai, Jake O'Brien, Coral Gartner, Raimondo Bruno, Benjamin Kele, Christoph Ort, Jeremy Prichard, Paul Kirkbride, Wayne Hall, Steve Carter, Jochen F. Mueller, Using quantitative wastewater analysis to measure daily usage of conventional and emerging illicit drugs at an annual music festival, Drug and Alcohol Review, 2013, 32, 6
  51. 51
    Harry Sumnall, James McVeigh, Michael J. Evans-Brown, Novel Psychoactive Substances, 2013,

    CrossRef

  52. 52
    Fiona Measham, Novel Psychoactive Substances, 2013,

    CrossRef

  53. 53
    Strategic Intelligence Management, 2013,

    CrossRef

  54. 54
    David M. Wood, Paul I. Dargan, Novel Psychoactive Substances, 2013,

    CrossRef

  55. 55
    Marie Claire Van Hout, Tim Bingham, “A Costly Turn On”: Patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors, International Journal of Drug Policy, 2012, 23, 3, 188

    CrossRef

  56. 56
    David P. Kasick, Curtis A. McKnight, Eleonora Klisovic, “Bath Salt” Ingestion Leading to Severe Intoxication Delirium: Two Cases and a Brief Review of the Emergence of Mephedrone Use, The American Journal of Drug and Alcohol Abuse, 2012, 38, 2, 176

    CrossRef

  57. 57
    M. Coppola, R. Mondola, 3,4-Methylenedioxypyrovalerone (MDPV): Chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online, Toxicology Letters, 2012, 208, 1, 12

    CrossRef

  58. 58
    Jacob M. McClean, Ara Anspikian, John W. Tsuang, Bath Salt Use: A Case Report and Review of the Literature, Journal of Dual Diagnosis, 2012, 8, 3, 250

    CrossRef

  59. 59
    Tom P. Freeman, Celia J. A. Morgan, James Vaughn-Jones, Nahida Hussain, Kash Karimi, H. Valerie Curran, Cognitive and subjective effects of mephedrone and factors influencing use of a ‘new legal high’, Addiction, 2012, 107, 4
  60. 60
    Pai-Kai Huang, Shawn M. Aarde, Deepshikha Angrish, Karen L. Houseknecht, Tobin J. Dickerson, Michael A. Taffe, Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats, Drug and Alcohol Dependence, 2012, 126, 1-2, 168

    CrossRef

  61. 61
    Marie Claire Van Hout, Rebekah Brennan, Curiosity killed M-Cat: A post-legislative study on mephedrone use in Ireland, Drugs: Education, Prevention, and Policy, 2012, 19, 2, 156

    CrossRef

  62. 62
    Julie A. Marusich, Kateland R. Grant, Bruce E. Blough, Jenny L. Wiley, Effects of synthetic cathinones contained in “bath salts” on motor behavior and a functional observational battery in mice, NeuroToxicology, 2012, 33, 5, 1305

    CrossRef

  63. 63
    Raimondo Bruno, Allison J. Matthews, Matthew Dunn, Rosa Alati, Fairlie McIlwraith, Sophie Hickey, Lucy Burns, Natasha Sindicich, Emerging psychoactive substance use among regular ecstasy users in Australia, Drug and Alcohol Dependence, 2012, 124, 1-2, 19

    CrossRef

  64. 64
    Laura Lindsay, Marjorie Lee White, Herbal Marijuana Alternatives and Bath Salts—“Barely Legal” Toxic Highs, Clinical Pediatric Emergency Medicine, 2012, 13, 4, 283

    CrossRef

  65. 65
    Suzan Owaisat, Robert B. Raffa, Scott M. Rawls, In vivo comparison of harmine efficacy against psychostimulants: Preferential inhibition of the cocaine response through a glutamatergic mechanism, Neuroscience Letters, 2012, 525, 1, 12

    CrossRef

  66. 66
    José Martínez-Clemente, Elena Escubedo, David Pubill, Jorge Camarasa, Interaction of mephedrone with dopamine and serotonin targets in rats, European Neuropsychopharmacology, 2012, 22, 3, 231

    CrossRef

  67. 67
    Tibor M. Brunt, Maarten W. Koeter, Raymond J. M. Niesink, Wim van den Brink, Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users, Psychopharmacology, 2012, 220, 4, 751

    CrossRef

  68. 68
    Renata Lisek, Wei Xu, Ekaterina Yuvasheva, Yi-Ting Chiu, Allen B. Reitz, Lee-Yuan Liu-Chen, Scott M. Rawls, Mephedrone (‘bath salt’) elicits conditioned place preference and dopamine-sensitive motor activation, Drug and Alcohol Dependence, 2012, 126, 1-2, 257

    CrossRef

  69. 69
    L. Ramoz, S. Lodi, P. Bhatt, A.B. Reitz, C. Tallarida, R.J. Tallarida, R.B. Raffa, S.M. Rawls, Mephedrone (“bath salt”) pharmacology: insights from invertebrates, Neuroscience, 2012, 208, 79

    CrossRef

  70. 70
    David M. Wood, Paul I. Dargan, Mephedrone (4-methylmethcathinone): What is new in our understanding of its use and toxicity, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 2, 227

    CrossRef

  71. 71
    Craig P. Motbey, Glenn E. Hunt, Michael T. Bowen, Suzanne Artiss, Iain S. McGregor, Mephedrone (4-methylmethcathinone, ‘meow’): acute behavioural effects and distribution of Fos expression in adolescent rats, Addiction Biology, 2012, 17, 2
  72. 72
    MJ Wright, Jr, SA Vandewater, D Angrish, TJ Dickerson, MA Taffe, Mephedrone (4-methylmethcathinone) and d-methamphetamine improve visuospatial associative memory, but not spatial working memory, in rhesus macaques, British Journal of Pharmacology, 2012, 167, 6
  73. 73
    Harry Meng, James Cao, Jiesheng Kang, Xiaoyou Ying, Junzhi Ji, William Reynolds, David Rampe, Mephedrone, a new designer drug of abuse, produces acute hemodynamic effects in the rat, Toxicology Letters, 2012, 208, 1, 62

    CrossRef

  74. 74
    Mariana Angoa-Pérez, Michael J. Kane, Dina M. Francescutti, Katherine E. Sykes, Mrudang M. Shah, Abiy M. Mohammed, David M. Thomas, Donald M. Kuhn, Mephedrone, an abused psychoactive component of ‘bath salts’ and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum, Journal of Neurochemistry, 2012, 120, 6
  75. 75
    Sebastian M. Toescu, Mephedrone: when science and policy fell out, Mental Health and Substance Use, 2012, 5, 3, 197

    CrossRef

  76. 76
    Janie Sheridan, Bruce Atmore, Bruce Russell, New Zealand to establish fit for purpose regulation for new psychoactive substances, Addiction, 2012, 107, 11
  77. 77
    MONICA J. BARRATT, SILK ROAD: EBAY FOR DRUGS, Addiction, 2012, 107, 3
  78. 78
    Fabrizio Schifano, John Corkery, A. Hamid Ghodse, Suspected and Confirmed Fatalities Associated With Mephedrone (4-Methylmethcathinone, “Meow Meow”) in the United Kingdom, Journal of Clinical Psychopharmacology, 2012, 32, 5, 710

    CrossRef

  79. 79
    M. Coppola, R. Mondola, Synthetic cathinones: Chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as “bath salts” or “plant food”, Toxicology Letters, 2012, 211, 2, 144

    CrossRef

  80. 80
    Michael H Baumann, Mario A Ayestas, John S Partilla, Jacqueline R Sink, Alexander T Shulgin, Paul F Daley, Simon D Brandt, Richard B Rothman, Arnold E Ruoho, Nicholas V Cozzi, The Designer Methcathinone Analogs, Mephedrone and Methylone, are Substrates for Monoamine Transporters in Brain Tissue, Neuropsychopharmacology, 2012, 37, 5, 1192

    CrossRef

  81. You have free access to this content81
    Adam R. Winstock, Luke Mitcheson, David A. Gillatt, Angela M. Cottrell, The prevalence and natural history of urinary symptoms among recreational ketamine users, BJU International, 2012, 110, 11
  82. 82
    Jane M. Prosser, Lewis S. Nelson, The Toxicology of Bath Salts: A Review of Synthetic Cathinones, Journal of Medical Toxicology, 2012, 8, 1, 33

    CrossRef

  83. 83
    D. M. Wood, P. I. Dargan, Understanding How Data Triangulation Identifies Acute Toxicity of Novel Psychoactive Drugs, Journal of Medical Toxicology, 2012, 8, 3, 300

    CrossRef

  84. 84
    M. Perrin, Y. Lecompte, O. Roussel, R. Le Boisselier, J. Bourgine, A. Coquerel, Traité De Toxicologie Médico-judiciaire, 2012,

    CrossRef

  85. 85
    Jayendra K. Patel, A worldwide yearly survey of new data in adverse drug reactions and interactions, 2012,

    CrossRef

  86. 86
    Dr Marie Claire Van Hout, Rebekah Brennan, “Bump and grind”: an exploratory study of Mephedrone users' perceptions of sexuality and sexual risk, Drugs and Alcohol Today, 2011, 11, 2, 93

    CrossRef

  87. 87
    R.L. Carhart-Harris, L.A. King, D.J. Nutt, A web-based survey on mephedrone, Drug and Alcohol Dependence, 2011, 118, 1, 19

    CrossRef

  88. 88
    Matthew D. Cook, Clean But Not Sober, Pediatric Emergency Care, 2011, 27, 9, 892

    CrossRef

  89. 89
    Simon L. Hill, Simon H. L. Thomas, Clinical toxicology of newer recreational drugs, Clinical Toxicology, 2011, 49, 8, 705

    CrossRef

  90. 90
    Thomas M. Penders, Richard Gestring, Hallucinatory delirium following use of MDPV: “Bath Salts”, General Hospital Psychiatry, 2011, 33, 5, 525

    CrossRef

  91. 91
    Péter Jankovics, András Váradi, László Tölgyesi, Szilvia Lohner, Júlia Németh-Palotás, Hilda Kőszegi-Szalai, Identification and characterization of the new designer drug 4′-methylethcathinone (4-MEC) and elaboration of a novel liquid chromatography–tandem mass spectrometry (LC–MS/MS) screening method for seven different methcathinone analogs, Forensic Science International, 2011, 210, 1-3, 213

    CrossRef

  92. 92
    TOBY LEA, ROBERT REYNOLDS, JOHN DE WIT, Mephedrone use among same-sex attracted young people in Sydney, Australia, Drug and Alcohol Review, 2011, 30, 4
  93. You have free access to this content93
    J Kehr, F Ichinose, S Yoshitake, M Goiny, T Sievertsson, F Nyberg, T Yoshitake, Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats, British Journal of Pharmacology, 2011, 164, 8
  94. You have free access to this content94
    Adam Winstock, Luke Mitcheson, John Ramsey, Susannah Davies, Malgorzata Puchnarewicz, John Marsden, Mephedrone: use, subjective effects and health risks, Addiction, 2011, 106, 11
  95. 95
    H.R. Sumnall, M. Evans-Brown, J. McVeigh, Social, policy, and public health perspectives on new psychoactive substances, Drug Testing and Analysis, 2011, 3, 7-8
  96. 96
    Adrian Derungs, Simeon Schietzel, Markus R. Meyer, Hans H. Maurer, Stephan Krähenbühl, Matthias E. Liechti, Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylpyrovalerone), Clinical Toxicology, 2011, 49, 7, 691

    CrossRef

  97. 97
    Tibor M. Brunt, Raymond J.M. Niesink, The Drug Information and Monitoring System (DIMS) in the Netherlands: Implementation, results, and international comparison, Drug Testing and Analysis, 2011, 3, 9
  98. 98
    Paul I. Dargan, Roumen Sedefov, Ana Gallegos, David M. Wood, The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone), Drug Testing and Analysis, 2011, 3, 7-8
  99. 99
    John M. Holden, Michael Fitzgerald, Gabriel Bussell, Vanessa Ehlers, Triadimefon supports conditioned cue preference, Behavioural Brain Research, 2011, 221, 1, 307

    CrossRef